http://www.dachshaus.cz/userfiles/image/ezi/3.8.html
http://www.itcorion.com/lcssv14.html
http://www.bilardohaber.com/51.html
http://krao.ru/files/oc/N7-1.html
http://adminguide.info/images/menu/2.1.html
http://www.zuccaciyespot.com/images/7.asp
http://acoferpinda.com.br/1.html
http://www.ilpalatoraffinato.it/10.html
http://www.pazam.co.il/18.html
http://www.petraplus.ru/test/3.5.html
http://adrianabertini.com.br/2.html
http://www.aldanube.com/5.html
http://www.satenkumasci.com/img/18.html
http://adviserbrasil.com.br/8.html
http://www.utp-ghana.com/UploadFiles/index13.html
http://www.latierradehadas.com.ar/fotos/index59.html
http://5stecnologia.com.br/3.html
http://www.satenkumasci.com/img/19.html
http://www.coppolavincenzosrl.it/classes/lv-8-7.html
http://www.studiolegaleambrosioiuorio.it/img/sf-8-5.html
SEARCH
Flash-spelare saknas/Javascript är inte aktiverat

Welcome to Dilafor


Dilafor develops pharmaceutical products from heparin derivatives with low anticoagulant activity. 
The company has a balanced product portfolio representing some highly promising ideas and innovations in obstetrics. Each of our projects addresses an important and unmet medical need. 



All our drug development projects are based on Low Anticoagulant Heparin (LAH). Although standard heparin has numerous biological functions, its potential as a treatment for indications other than those currently approved is limited by its anticoagulative properties. Dilafor has produced several forms of LAH. 
One of them, Tafoxiparin is presently in development for the prevention and normalization of protracted labor. An exploratory Proof of Concept phase II clinical study comprising a total of 263 women has been completed.The drug was shown to be safe and well tolerated, and analyses of the results indicate that treatment with tafoxiparin can provide beneficial effects.


Most important, the results of the study gave Dilafor a solid base to plan in detail the further and ongoing clinical development program for a number of indications within the obstetric field.


 



Technologies & Discovery
Learn more about drug development at Dilafor.
Obstetrics
Learn more about our work in obstetrics.
NEWS
2015-02-25
Dilafor announces positive results from a multi dosing safety and pharmacokinetic clinical study
STOCKHOLM, SWEDEN February 25, 2015. Dilafor AB, a Karolinska Development portfolio company, announced today the completion of a safety and pharmacokinetic multi dosing clinical study with the candidate drug tafoxiparin. The purpose of the study was to evaluate different clinical administration routes and different dose levels of tafoxiparin in healthy female volunteers. The results will give guidance on the dosages to be used in the Phase II trial in labor induction expected to start in end 2015.
>>
2014-10-08
Dilafor signs supply and partnership agreement with Opocrin
Dilafor signs supply and partnership agreement with Opocrin
>>
2014-02-20
Dilafor enters into a license and partnership agreement with Lees Pharmaceutical
>>

Copyright © 2001-2015. All rights reserved.